Stockwinners Market Radar for August 26, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:38 EDT Nautilus Biotechnology director buys 37K shares of common stock - In a regulatory filing, Nautilus Biotechnology disclosed that its board member Matthew McIlwain bought 37K shares of common stock on August 24th in a total transaction size of $285K. Shares of Nautilus Biotechnology are up 4.2% after-hours at $8.04.

20:32 EDT Bolt Biotherapeutics and Innovent to collaborate on new oncology ISAC programs - Innovent Biologics (IVBXF) and Bolt Biotherapeutics (BOLT) announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate, or ISAC, candidates. The parties will leverage Innovent's proprietary therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolt's advanced ISAC technology and myeloid biology expertise to create three new cancer treatments with the potential to provide significant benefit to patients. The Boltbody ISAC platform combines a tumor-targeting antibody, a stable non-cleavable linker, and a proprietary immune stimulant. Boltbody ISACs unite the precision of antibody targeting with the power of innate and adaptive immune system response. Under the agreement, Innovent has the rights to all three programs in Greater China, and retains an option to license global rights for one program, as well as rights for all territories except North America for another program. Bolt retains the option to license global rights outside of Greater China for one program, and North American rights for another program. Innovent is responsible for all research and development costs through clinical proof-of-concept. Upon review of the initial clinical proof-of-concept data, the companies can exercise licensing options for continued development and exclusive commercialization rights in specific territories on a program-by-program basis. Bolt will receive an upfront payment of $5M in cash from Innovent at signing and a possible future equity investment of up to $10M. Furthermore, both Innovent and Bolt are eligible to receive additional milestones payments and royalties associated with the development and commercialization of products in each other's territories."

19:41 EDT Marcus & Millichap brokers $58M housing sale in Huntington Beach - Marcus & Millichap announced the sale of Skandia Mobile Country Club, a 167-unit mobile home complex in Huntington Beach, California. The property sold for $58M, or $347,305 per space.

18:21 EDT NAIA announces partnership with Henry Schein Medical - The National Association of Intercollegiate Athletics announced that it has come to terms with Henry Schein Medical, the medical business of Henry Schein, as its 'Official Sports Medicine Partner' through June 2022. The one year agreement will provide NAIA members a discounted rate for sports medicine services on their campuses, giving institutions an affordable option of medical services for their student-athletes. Supplies can be selected from a variety of product categories offered by Henry Schein Medical's Athletics & Schools business, including: infection control, hot and cold therapy treatment, physical therapy equipment, athletic tapes and bandages, rehydration, and nutrition. Additionally, Henry Schein Medical's Athletics & Schools business will provide athletic training supplies for all NAIA Championships.

17:57 EDT Four Corners Property Trust announces acquisition of Caliber Collision for $1.4M - Four Corners Property Trust announces the acquisition of a Caliber Collision property for $1.4M. The property is located in a strong retail corridor in Virginia and is corporate-operated under a net lease with approximately eleven years of term remaining. The transaction was priced at a 6.4% cap rate on rent today and exclusive of transaction costs, or 6.5% inclusive of a contractual rent increase in December 2021.

17:39 EDT PotlatchDeltic lifts closure of public access to Idaho timberlands - PotlatchDeltic announced changes to public access to its Idaho timberlands. Due to recent rainfall and lower temperatures in the region, fire risk has declined. As a result, the temporary public access ban announced on July 22 will be lifted effective Friday, August 27. PotlatchDeltic timberlands will be open for recreational activities, including camping, hunting and fishing, in accordance with company recreation policies.

17:26 EDT Capital City Bank increases cash dividend 6.7% to 16c per share - Capital City Bank declared a quarterly cash dividend on its common stock of 16c per share. It represents a 6.7% increase over the prior quarter of 15c. The dividend produces an annualized rate of 64c per common share and is payable on September 27 to shareowners of record as of September 13. The annualized dividend yield is 2.74% based on a closing stock price of $23.36 on August 25.

17:09 EDT Cyxtera Technologies director buys 93.6K shares of common stock - In a regulatory filing, Cyxtera Technologies disclosed that its board member Greg Waters bought 93.6K shares of common stock on August 25th in a total transaction size of $785K. Shares of Cyxtera Technologies are up 4.6% after-hours at $8.80.

16:58 EDT EastGroup Properties raises quarterly dividend 13.9% to 90c from 79c per share - The dividend is payable on October 15 to shareholders of record of Common Stock on September 30. This dividend is the 167th consecutive quarterly distribution to EastGroup's shareholders and represents an annualized dividend rate of $3.60 per share. EastGroup has increased or maintained its dividend for 29 consecutive years. The company has increased it 26 years over that period, including increases in each of the last 10 years.

16:43 EDT Revolve Group director Stolzman sells $240K in company shares - Revolve Group director Marc Stolzman disclosed in a filing that he had sold 3,883 shares of company stock at an average price of $61.94 per share on August 24, for a total transaction amount of $240,513.

16:39 EDT Wolverine World Wide updates liquidity of capital structure after note sale - Wolverine World Wide provided an update on actions it has taken to increase the liquidity and flexibility of its capital structure, primarily through the sale of $550M of 4.000% Senior Notes due 2029 which closed. The Company used the net proceeds from the sale of the Notes, together with borrowings under its amended senior credit facility, to redeem all of its outstanding 5.000% Senior Notes due 2026 and 6.375% Senior Notes due 2025 and to pay all related fees and expenses. "The Company's consistently strong cash flow over the last several years has resulted in a very healthy balance sheet," said Mike Stornant, Senior Vice President and Chief Financial Officer. "This performance, coupled with our positive outlook for the future, has allowed us to access the high-yield credit market at an opportune time and achieve a very favorable outcome. The recent bond refinancing actions will deliver annual interest expense savings of approximately $9.5 million that will benefit us immediately. The new notes also provide longer tenor. We are well positioned to continue to invest in driving profitable growth, especially for our fast-growing performance brands, led by Merrell, Saucony, and Sweaty Betty."

16:35 EDT MVB Financial expands investment in payment, distribution platform Interchecks - MVB Financial announced the expansion of its investment in payment distribution platform Interchecks Technologies. MVB acquired its initial stake in Interchecks in 2019. The additional investment announced will increase MVB's interest in Interchecks to 16%. MVB's overall Fintech investment portfolio has produced a cumulative IRR of nearly 200% since 2016. Interchecks has achieved notable success in the gaming industry segments of online sports betting, daily fantasy sports and iGaming, a key area of focus for MVB. In partnership with Visa Direct, which provides Interchecks with direct access to its payment rails, the company has built a real-time payment infrastructure that is leveraged by MVB's largest clients and a growing number of the more than 30 gaming companies that currently bank with MVB. "As an early investor in our company and given the many synergies between us, MVB is an ideal partner for Interchecks as we seek to grow our business in the online gaming segment and other high-growth industries," said Dylan Massey, CEO of Interchecks. "We also look forward to working with the MVB Edge Ventures team on the rollout of its GRAND technology, which will provide cheaper and faster payments from a modern bank account. This is synergistic with our efforts throughout our history at Interchecks to provide real-time payments to the online sports betting space."

16:32 EDT Dime Community authorizes new stock repurchase program for up to 5% of stocks - Dime Community approved a new stock repurchase program, which authorizes the purchase of up to 2,043,968 shares, or 5% of its currently outstanding common stock, upon completion of its existing previously authorized stock repurchase program. 49,230 shares remain eligible for repurchase under the existing stock repurchase plan. Any shares repurchased will be held as treasury stock and will be available for general corporate purposes.

16:31 EDT Caesars purchases minority interest in Horseshoe Baltimore from JV partner - Caesars Entertainment purchased a minority interest in Horseshoe Baltimore from one of its joint venture partners. As a result of this transaction, Caesars now owns 76% of Horseshoe Baltimore and will consolidate the results of the property on Caesars' financial statements.

16:28 EDT Dell Technologies ends Q2 with remaining performance obligations of $46B - Dell Technologies ended the quarter with remaining performance obligations of $46B, up 24% and cash and investments of $13.6B. The company has paid down $5.5B in debt year-to-date and expects to pay down at least $16B for its fiscal year 2022. "We had strong results again this quarter, with all business units growing," said Tom Sweet, CFO, Dell Technologies. "We are creating long-term value by taking share, pursuing high-value growth opportunities and profitably growing and modernizing our core business. For example, in the storage space, VxRail orders were up 34% and PowerStore continues to ramp up nicely."

16:25 EDT Navios Maritime Partners announces merger with Navios Acquisition - Navios Maritime Partners (NMM), an international owner and operator of dry cargo vessels, and Navios Maritime Acquisition Corp. (NNA), an international owner and operator of tanker vessels, announced a definitive transaction agreement providing for a combination of Navios Partners and Navios Acquisition in a transaction in which shareholders of Navios Acquisition will receive 0.1275 of a common unit of Navios Partners for each outstanding common share of Navios Acquisition. All of Navios Acquisition's outstanding 8.125% First Priority Ship Mortgage Notes, due on November 15 will be redeemed in accordance with their terms with the proceeds of a cash contribution from Navios Partners and newly arranged secured term loan financings. Angeliki Frangou, Chairwoman and Chief Executive Officer, stated, "We are announcing a transformative transaction. The combined entity will be the largest U.S. publicly-listed shipping company in terms of vessel count, with 15 vessel types diversified across three segments, servicing more than 10 end markets. About one-third of our fleet will be in each of the dry bulk, containership and tanker segment. We believe that this combination will result in a stronger, more resilient entity, mitigating sector specific cyclicality. This should enable us to capitalize on opportunities throughout the industry and provide even returns to our stakeholders across cycles. This combination of two companies with similar core values and beliefs, as it relates to our service offerings, will allow us to continue to deliver the high-quality service that our customers expect. We have a proven model to execute seamless combinations, as evidenced by our prior successful roll-up transactions, and we anticipate a smooth execution for this combination as well." The current value of the combined company's vessels is estimated at $4.2 billion based upon the average of publicly available broker reports; the combined company will also have an enterprise value of approximately $2.25 billion. With a $1.6 billion pipeline of contracted revenue coupled with about 47,634 available days in 2022, the combined fleet is well-positioned to take advantage of the healthy dry cargo markets as well as any future upturn in the tanker market.

16:24 EDT Gap reports Q2 Old Navy Global comps flat from last year and up 18% from 2019 - Gap Global comparable sales declined 5% year-over-year and increased 3% versus 2019. Banana Republic Global comparable sales were up 41% year-over-year and down 5% versus 2019. Athleta comparable sales grew 13% year-over-year and 27% versus 2019.

16:21 EDT Gap CEO says Q2 sales were highest in over a decade - "Our talented teams delivered our highest second quarter net sales in over a decade. Our strategy is driving growth as evidenced by continued strength at Old Navy and Athleta, Gap Brand's second consecutive quarter of positive 2-year comparable sales in North America, and momentum gaining at Banana Republic. Stepped-up marketing investments, improved brand management, and technology enhancements are paying off as our brand power cuts through," said Sonia Syngal, CEO, Gap Inc. "I look forward to our Integrated Loyalty Program and Old Navy's inclusive shopping experience, BODEQUALITY, taking hold in the back half, both key components of our Power Plan 2023, and important drivers of long-term sustainable growth."

16:20 EDT Donerail responds to Turtle Beach press release - The Donerail Group, one of the largest shareholders of Turtle Beach, responded to Turtle Beach's press release issued on August 23: "While Turtle Beach stated in its release that Donerail's public statements had been "misleading", the Company failed to detail how any of Donerail's previous public statements were misleading and, instead, proceeded to present its own narrative misrepresenting Donerail's acquisition efforts to date. We read Turtle Beach's August 23rd press release with great disappointment, as the Turtle Beach Board of Directors (the "Board") has grossly distorted the facts and circumstances regarding Donerail's acquisition efforts in order, we believe, to further its self-serving entrenchment efforts. In the Company's release, we are at least gratified that the Board acknowledged its rejection of our revised, heightened $36.50 offer, which it claims was due to fact that the Board "did not view Donerail's acquisition price to be sufficient". We believe all shareholders deserve an explanation as to why this Board outright rejected a proposal that would provide a 42% premium from last Wednesday's share price and a 32% premium from yesterday's closing price. And while our principal concern begins and ends with the Company's distorted view of value and stubborn refusal to explore value-maximizing acquisition offers, the balance of the Company's August 23rd press release served as an unexpected effort to misdirect shareholders on the recent series of events, introducing significant concern regarding the Board's ability to credibly uphold its fiduciary obligations to shareholders... Let shareholders not be confused: Donerail is one of the largest shareholders of the Company; has engaged with the Company in good faith in an attempt to acquire it; has provided robust and comprehensive details to the Board and its financial advisor regarding our prospective acquisition financing; and has attempted for months to review confirmatory diligence to confirm our price and finalize our bid. But the most salient fact remains: the Board has rejected a bona fide $36.50 offer with the Company's stock price trading meaningfully lower. We do not understand the Board's actions, and shareholders have a right to be concerned. Turtle Beach is a unique, strategic and defensive brand with highly durable and highly visible cash flows. Notwithstanding the disappointing quality of engagement heretofore with the Board, we are hopeful that the Board recognizes the Company needs to be sold immediately and that we stand willing to engage as a prospective buyer."

16:18 EDT Peloton sinks 12% to $100.02 following Q4 results

16:17 EDT VMware reports Q2 RPO $11.2B, up 8% from last year - In Q2 of FY22, combination of subscription and SaaS and license revenue was $1.51B, an increase of 12% from the second quarter of fiscal 2021. Subscription and SaaS revenue for the second quarter was $776 million, an increase of 23% year-over-year. Subscription and SaaS ARR for the second quarter was $3.15B, an increase of 26% year-over-year.

16:15 EDT MorphoSys, Incyte get EC conditional MA for Minjuvi-lenalidomide combo for DLBCL - MorphoSys (MOR) and Incyte (INCY) announced that the European Commission has granted conditional marketing authorization for Minjuvi, tafasitamab, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant . The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2021 recommending the conditional marketing authorization of Minjuvi. "People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis. However, with the EC's approval of Minjuvi, eligible patients now have a new and much needed treatment option," said Herve Hoppenot, Chief Executive Officer, Incyte. "We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment." "The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, "said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. "DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse after initial therapy." The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant . The results showed best objective response rate of 56.8%, primary endpoint, including a complete response rate of 39.5% and a partial response rate of 17.3%, as assessed by an independent review committee. The median duration of response was 43.9 months after a minimum follow up of 35 months, secondary endpoint. Tafasitamab together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for tafasitamab include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.

16:11 EDT MorphoSys, Incyte say EC grants MA for Minjuvi-lenalidomide combo for DLBCL - MorphoSys and Incyte announced that the European Commission has granted conditional marketing authorization for Minjuvi, tafasitamab, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant . The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2021 recommending the conditional marketing authorization of Minjuvi. "People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis. However, with the EC's approval of Minjuvi, eligible patients now have a new and much needed treatment option," said Herve Hoppenot, Chief Executive Officer, Incyte. "We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment." "The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, "said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. "DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse after initial therapy." The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant . The results showed best objective response rate of 56.8%, primary endpoint, including a complete response rate of 39.5% and a partial response rate of 17.3%, as assessed by an independent review committee. The median duration of response was 43.9 months after a minimum follow up of 35 months, secondary endpoint. Tafasitamab together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for tafasitamab include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.

16:09 EDT Whirlpool names Joseph Liotine COO - Whirlpool promoted Joseph Liotine to the position of President and COO effective September 1. Liotine is currently Executive VP and President of Whirlpool's North America Region. In addition, he leads both the Global KitchenAid Small Domestic Appliances business as well as Global Information Systems. Liotine began his career with Whirlpool Corporation in 2004 serving the company in a variety of sales, strategy and marketing roles. Winn Everhart will succeed Liotine as the company's Executive VP and President of the North America Region. Everhart joined Whirlpool in October 2020 as Senior VP overseeing U.S. commercial and business operations.

16:07 EDT Marvell CEO says Q2 growth 'by the data center' - "Marvell delivered record revenue of $1.076 billion in the fiscal second quarter, above the midpoint of guidance, growing 29 percent sequentially and 48 percent year over year. Growth was driven by the data center, which now represents Marvell's largest end market at 40 percent of total revenue, benefiting from our growing momentum in the fast-growing cloud infrastructure market," said Matt Murphy, Marvell's President and CEO. "I am pleased that stand-alone Marvell and the acquired Inphi businesses both contributed to our strong year-over-year revenue growth. We expect year-over-year revenue growth will accelerate in the third quarter, led by substantial contributions from the cloud data center market. In addition, we expect our 5G business to continue to grow with strong sequential revenue growth in the third quarter, and a significant step up projected in the fourth quarter."

16:05 EDT Workday sees Q3 subscription revenue $1.156B-$1.158B - "We delivered an incredibly strong Q2, driven by exceptional execution against a rapidly improving backdrop," said Robynne Sisco, president and chief financial officer, Workday. "As a result, we are raising our fiscal 2022 guidance for subscription revenue to a range of $4.500 billion to $4.510 billion, growth of 19%. We expect third-quarter subscription revenue of $1.156 billion to $1.158 billion, 20% growth at the high end. We are also raising our fiscal 2022 non-GAAP operating margin guidance to 21.0%."

15:48 EDT Altria Group raises quarterly dividend 4.7% to 90c from 86c per share - The quarterly dividend is payable on October 12 to shareholders of record as of September 15. The ex-dividend date is September 14. The new annualized dividend rate is $3.60 per share, representing a yield of 7.4% based on Altria's closing stock price of $48.65 on August 25.

15:20 EDT NextGen Healthcare issues statement regarding board refreshment process - NextGen Healthcare issued the following statement on behalf of all members of the NextGen Healthcare Board of Directors, other than Sheldon Razin and Lance Rosenzweig: "Sheldon Razin and Lance Rosenzweig are once again obstructing the Board's efforts to drive Board refreshment and reach a mutually agreeable resolution with respect to the proxy contest they have initiated. As previously announced, NextGen Healthcare's Board has been working with Spencer Stuart since February to identify new, independent directors that bring relevant expertise and perspectives to support the Company's continued success and strategic execution. This work led to the recent announcement of two new independent directors: Geraldine McGinty, MD, MBA, FACR and Pamela S. Puryear, PhD, MBA. Dr. McGinty and Dr. Puryear bring substantial experience relevant to the healthcare industry, including in executive management, operations, clinical practice and talent development, while also advancing board diversity. As part of the Board's work to identify new, highly qualified director candidates, NextGen Healthcare recently announced that the Board would consider the four independent individuals nominated by Sheldon and Lance consistent with its policies and procedures for considering proposed stockholder nominees. The Chair of the Nominating and Governance Committee has attempted, in good faith, to schedule interviews with these four individuals and Spencer Stuart. We believe these conversations are important to better understand the respective candidate's experience and interest in joining the Board and to also provide them the opportunity to ask questions about the Company. Certain of these candidates have expressed their openness to having these conversations. However, Sheldon and Lance obstructed these efforts... It is clear who is imperious and who wants control - it is the 47-year board member, Sheldon Razin, who is unwavering in his unwarranted, disruptive, costly proxy contest, which he initiated to advance his own interests - preserving his seat on the Board, as he has said, forever. Shareholders should remember: When Sheldon Razin's role as Board Chair concluded, NextGen Healthcare was a deteriorating business with unproductive R&D investments and a disenfranchised customer base. Moreover, Sheldon's capital allocation plan prioritized $400 million in dividends that thwarted sustainable high growth and largely benefitted him personally. It was only after we established new leadership that we could begin to turn around the Company and position it as a market leader. We are committed to acting in the best interests of ALL shareholders and again extend an invitation to the four director nominees to speak with us."

14:35 EDT LGL Systems Acquisition holders approve combination with IronNet - LGL Systems Acquisition (DFNS) announced the results for the six proposals considered and voted upon by its stockholders at its special meeting. LGL reported that each of the six proposals, including the proposals giving effect to the previously announced business combination between LGL and IronNet Cybersecurity, was approved. LGL also announced that it has completed its business combination with IronNet, resulting in the combined company being renamed as "IronNet, Inc.", with its common stock and warrants to commence trading on the New York Stock Exchange on August 27 under the ticker symbols "IRNT" and "IRNT.WS", respectively.

14:13 EDT MetLife, Norges acquire One Memorial Drive for $825M - MetLife Investment Management, the institutional asset management business of MetLife, and Norges Bank Investment Management, the asset management division of Norges Bank, announced the acquisition of One Memorial Drive in Cambridge, Massachusetts for $825M. One Memorial Drive is a 17-story, Class A office building located on the Charles River with 409,422 square feet of leasable space. Built in 1986 and renovated in 2018, the fully occupied property has two long-term tenants, InterSystems Corporation and Microsoft.

14:11 EDT Gap acquires e-commerce startup Drapr - Gap said it has acquired Drapr, an e-commerce startup and online application based on technology that enables customers to create 3D avatars and virtually try on clothing. "Drapr is designed to help customers find the best clothing size and fit for their personal style and body type, while helping retailers reduce unnecessary returns," Gap said in a statement. Terms of the deal were not disclosed.

13:11 EDT Coinbase names Facebook's Kate Rouch as Chief Marketing Officer - Coinbase (COIN) announced that Kate Rouch is its new Chief Marketing Officer. Rouch joins Coinbase after more than a decade at Facebook (FB), most recently serving as Global Head of Brand and Product Marketing for Instagram, WhatsApp, Messenger, Facebook app, Public Affairs and the Facebook company. "Kate's experience at a company with the scale and impact of Facebook will be invaluable as we continue building our brand, growing our teams and working to bring millions more people into the cryptoeconomy," Coinbase said in a statement.

12:46 EDT Nvidia acquires DeepMap, maker of maps for autonomous vehicles - Nvidia said has acquired DeepMap, a startup dedicated to building high-definition maps for autonomous vehicles. Terms of the deal were not disclosed. Reference Link

12:33 EDT Sorrento Therapeutics reports preclinical results for mRNA vaccine for COVID-19 - Sorrento Therapeutics announced preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of proprietary designer Spike-encoding mRNAs to elicit cellular and humoral immunity against the early WA-1 virus as well as the predominant and emerging variants of concern, including Alpha, Beta, Gamma, Delta, and Lambda. Currently marketed vaccines have demonstrated reduced efficacy against the major SARS-CoV-2 emerging VOCs2, with declining efficacy over time3. Novel approaches are needed that improve durability for both humoral and cellular immunity against current and emerging variants. The MuVaxx lymphatic drug delivery device is designed to deliver vaccine into the epidermis to potentially enable access and increased exposure to dendritic cells in the skin and in lymph nodes at lower doses than with intramuscular administration. Intramuscular STI-mRNA compared to the IM LNP-mRNA showed a dramatic 400% improvement in cellular immunity as measured by cytokine production of spike specific CD8 T cells. This elevated level of cellular immune response was also observed at 1/10th of the STI-mRNA dose using the MuVaxx lymphatic drug delivery device. STI-mRNA also demonstrated similar humoral immunity as compared to the IM LNP-mRNA reference and IM STI-mRNA. These preclinical findings are significant as cellular immunity is critical for impeding virus replication and conferring long-term protection. Additionally, current approved LNP-mRNA vaccines have been shown to potentially have dose-dependent side effects4. The STI-mRNA and MuVaxx combination appear to elicit a similar humoral response and an elevated cellular response against the SARS-CoV-2 virus, at a fraction of the current vaccine doses. These initial preclinical results provide the basis for Sorrento to move forward aggressively with IND-enabling studies with our MultiValent STI-mRNA vaccine candidate.

12:00 EDT Regis falls -10.0% - Regis is down -10.0%, or -70c to $6.30.

12:00 EDT SelectQuote falls -43.7% - SelectQuote is down -43.7%, or -$6.27 to $8.08.

12:00 EDT Coty rises 13.7% - Coty is up 13.7%, or $1.12 to $9.36.

11:46 EDT Tyson Foods to invest $300M to build new plant in Danville, Virginia - Tyson Foods will invest $300M to build a new, fully-cooked plant in Danville, Virginia, company officials announced. The project is part of the company's commitment to meet increasing demand and deliver on its strategy of accelerating long-term growth. The new facility is expected to create nearly 400 jobs when production begins in the spring of 2023. The company will construct a 325,000-square-foot facility, primarily for the production of fully-cooked Tyson branded chicken products, including Any'tizer Snacks and Chicken Nuggets. The company has committed to purchase 60 million pounds of Virginia-grown chicken over the next three years. The facility will be built in Cane Creek Centre, an industrial park jointly owned by the City of Danville and Pittsylvania County.

11:32 EDT Sonoco-Alcore to increase tube and core prices in EMEA - Sonoco-Alcore S.a.r.l. announced that due to inflationary pressures on the business, it will raise prices by 8 percent on all tube and core grades sold in the company's EMEA regions. The increase will be effective for all shipments made on or after September 1. "We have seen further considerable increases in the cost of raw materials since beginning of the year, and we expect these to further escalate. In addition, we face significant inflationary costs for transport, packaging, energy and labour. We have taken continued efforts to optimize and implemented saving programs but cannot absorb these massive increases anymore," said Karsten Kemmerling, Division VP - Sales & Marketing EMEA. Sonoco Alcore S.a.r.l. is wholly owned by Sonoco and operates 24 tube and core plants and five paperboard mills in Europe.

11:06 EDT Deca Dental Group announces investment from Blackstone Tactical Opportunities - DECA Dental Group announced a strategic investment from funds managed by Blackstone Tactical Opportunities. This partnership will help fuel DECA's continued expansion, giving more dentists a platform to provide high quality, patient-centric, and convenient care to communities across the country. Founded in Dallas in 2008, DECA has nearly 100 affiliated dental practices with a network of offices in Texas, Florida and Washington. Terms of the transaction were not disclosed.

11:02 EDT Apple introduces News Partner Program - Apple introduced the News Partner Program, a new slate of initiatives to expand Apple's work with and support for journalism. Apple said in a statement that the News Partner Program "aims to ensure Apple News customers maintain access to trusted news and information from many of the world's top publishers, while supporting publishers' financial stability and advancing efforts to further media literacy and diversity in news coverage and newsrooms." The News Partner Program is designed for subscription news publications that provide their content to Apple News in Apple News Format.

10:57 EDT PureTech Health PLC (ADS) trading halted, volatility trading pause

10:34 EDT Flora Growth drops 8% to $9.69 following White Diamond short report

10:27 EDT Universal Security Instruments trading halted, news pending

10:05 EDT AbbVie announces positive reimbursement recommendation for AML - AbbVie announced that the CADTH pCODR Expert Review Committee recommended that Venclexta in combination with azacitidine should be reimbursed for the treatment of patients with newly diagnosed acute myeloid leukemia who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, only if the conditions listed are met.

10:00 EDT Abercrombie & Fitch falls -12.6% - Abercrombie & Fitch is down -12.6%, or -$5.00 to $34.80.

10:00 EDT SelectQuote falls -45.1% - SelectQuote is down -45.1%, or -$6.47 to $7.88.

10:00 EDT Coty rises 17.7% - Coty is up 17.7%, or $1.46 to $9.69.

09:47 EDT Abercrombie & Fitch falls -10.6% - Abercrombie & Fitch is down -10.6%, or -$4.23 to $35.57.

09:47 EDT SelectQuote falls -41.3% - SelectQuote is down -41.3%, or -$5.93 to $8.42.

09:47 EDT Pure Storage rises 12.4% - Pure Storage is up 12.4%, or $2.59 to $23.54.

09:44 EDT DealerPolicy announces $110M Series C funding led by Goldman Sachs - DealerPolicy announced its $110 million Series C investment led by the Growth Equity business within Goldman Sachs Asset Management with participation from existing investors including 3L Capital and Hudson Structured Capital Management. The new investment will be used to accelerate the growth of the company's next-generation finance and insurance offerings for both dealers and car buyers, enabling automotive insurance to be seamlessly integrated online and at the point-of-sale. Goldman Sachs' Paul Pate will join the company's board of directors. DealerPolicy will expand its operations to further develop and embed modern day insurance throughout the entire car shopping and ownership experience. To expedite the development and roll-out of its insurance distribution and fulfillment solutions with its major insurance carrier partners, the company intends to triple its product and engineering teams over the next 12 months by hiring new talent. Additionally, the company will increase investments in strategic partnerships.

09:34 EDT Two NextGen directors file proxy to nominate four board members - Sheldon Razin, who collectively with Lance Rosenzweig and the other participants in his solicitation owns approximately 15.2% of the outstanding common shares of NextGen Healthcare, yesterday filed a preliminary proxy statement with the Securities and Exchange Commission in connection with the company's annual meeting scheduled for October 13. Razin and Rosenzweig currently serve on NextGen's board. In addition to himself and Mr. Rosenzweig, Razin has nominated four additional individuals - Kenneth Fearn, Ramon Gregory, Julie Schoenfeld and Ruby Sharma - for election to the board at the annual meeting. Razin and Rosenzweig commented: "It's unfortunate that we have been forced to take the extraordinary step of nominating an alternative slate of director candidates for election at this year's Annual Meeting. Hopefully our fellow shareholders understand that we wouldn't have gone down this road without believing - beyond any doubt - that facilitating meaningful Board change is the key to putting NextGen Healthcare back on a path to market leadership and organic growth."

09:31 EDT Wipro announces AI partnership with DataRobot - Wipro announced a global strategic partnership with DataRobot, a leader in Augmented Intelligence. The partnership will deliver Augmented Intelligence at scale to help customers become AI driven enterprises and accelerate their business impact. DataRobot's Augmented Intelligence platform complements Wipro's expertise in enterprise AI. This collaboration will help accelerate the execution of AI strategy and will ensure quicker "data to value" for businesses. The partnership will streamline the process of infusing AI-led intelligence into customer business decisions and positively impact their bottom line.

09:21 EDT Diana Shipping announces time charter contract for M/V Selina - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ASL Bulk Shipping HK Limited, for one of its Panamax dry bulk vessels, the m/v Selina. The gross charter rate is US$26,500 per day, minus a 5% commission paid to third parties, for a period until minimum June 15, 2022 up to maximum September 15, 2022. The charter is expected to commence on September 1, 2021. The m/v Selina is currently chartered, as previously announced, to ST Shipping and Transport Pte. Ltd., Singapore, at a gross charter rate of US$11,000 per day, minus a 5% commission paid to third parties. The "Selina" is a 75,700 dwt Panamax dry bulk vessel built in 2010. The employment of "Selina" is anticipated to generate approximately US$7.53 million of gross revenue for the minimum scheduled period of the time charter.

09:18 EDT Information Analysis appoints James Benoit as Chairman, CEO - Information Analysis announced the appointment of Jamie Benoit as its Chairman of the Board and Chief Executive Officer effective August 26, 2021. "Under his leadership and through acquisitive and organic growth, Benoit will aggressively strive to reposition the company as a disruptive technology and commercial enablement leader in government and global private sector verticals," the company said. Benoit will work alongside former CEO Stan Reese, who will remain President and continue to manage operations at IAI. Prior to joining IAI, Benoit served as Chief Executive Officer of FedData.

09:17 EDT Matterport aenters agreement to develop GovCloud offering with In-Q-Tel - Matterport marks its expansion into the public sector with an agreement to develop a compliant Government Cloud offering and strategic partnership with In-Q-Tel, Inc. Matterport sees potential for new use cases to across federal agencies, from the Department of Defense and the Intelligence Community to civilian agencies like the Federal Emergency Management Agency and the Department of Health and Human Services. Matterport allows anyone to quickly create accurate and immersive 3D digital twins of physical spaces to more effectively understand, analyze, manage and utilize buildings and spaces. Through the use of Matterport's technology, federal agencies will be able to digitize and index government facilities, infrastructure and other assets such as airplanes, ships and submarines into a library of accurate and immersive Matterport 3D spaces that can be accessed anytime, anywhere for a myriad of situations. For example, in the event of an emergency, digital twins of buildings, roads, bridges, tunnels, water supplies or electrical grids can be instantly viewed and analyzed by authorized users to respond more efficiently, collaboratively, and more effectively.

09:13 EDT Comtech gets $2.1M of funding for EEE parts management, engineering services - Comtech Telecommunications announced that during its fourth quarter of fiscal year 2021, it was awarded $2.1M of additional funding from a major U.S. prime contractor in support of NASA's Space Launch System Control System Electronics. The contract consolidates requirements for high reliability electrical, electronic and electromechanical parts and engineering services. The total contract value is now $10.3M and fully funded.

09:11 EDT EnWave, Dole Worldwide enter strategic partnership with nutrition solutions - EnWave Corporation and Dole Worldwide Food & Beverages Group, a division of Dole Asia Holdings, have announced plans for a global Strategic Partnership to develop Innovative Nutrition Solutions using fruits and vegetables. EnWave and Dole have been collaborating since late 2020. EnWave's Radiant Energy Vacuum technology provides a gentle, rapid drying solution that allows for the production of innovative, nutritious and convenient food applications while partnering with Dole in achieving its company purpose. Dole has placed an order for purchase of EnWave's patented equipment to accelerate internal product development and allow for focused market trials in select regions. The strategic partnership with Dole will leverage the company's industry-leading brand alongside EnWave's patented dehydration technology to bring better-for-you snacking options to its global customer base, as part of Dole's Sunshine for All commitment. Both companies are intent on growing this partnership further in the near future.

09:09 EDT Virpax announces MMS019 manufacturing and supply agreement - Virpax Pharmaceuticals announced that it has entered into a commercial manufacturing and supply agreement with Seqens The agreement with Seqens provides for both the supply material for Virpax's clinical studies as well as the long-term commercial supply of MMS019. Seqens will conduct process development and validation of additional large scale commercial quantities of MMS019 at its facilities in Devens and Newburyport, Massachusetts. "Establishing a collaboration with a strong partner capable of supplying clinical and commercial scale quantities of MMS019 is another important advancement in our MMS019 product development strategy. Seqens has a demonstrated expertise in developing and manufacturing highly-complex molecules for large scale production," said Anthony Mack, Chairman and CEO of Virpax. "Importantly, we expect this collaboration to support future development and supply additional Molecular Envelope Technology programs under development, including Envelta and PES200, our post-traumatic stress disorder product candidate," concluded Mr. Mack.

09:07 EDT LegalZoom, Defy Ventures partner to address barriers of inequity - LegalZoom.com has partnered with Defy Ventures, a nonprofit organization dedicated to helping end recidivism by training formerly incarcerated people to become entrepreneurs. Through a philanthropic donation and the sharing of the company's unique resources, LegalZoom will support Defy Ventures' efforts to equip its clients with new skills, connections and consulting support so they can start a new life and achieve economic independence. LegalZoom is taking action to help attack and solve the challenges that justice-involved individuals, especially women and minorities, often face pre- and post-release. By partnering with Defy Ventures, which aims to shift mindsets to give people with criminal histories their best shot at a second chance, the company intends to make the path to business ownership more equitable and accessible. As part of the partnership, LegalZoom will fund the first women's prison cohort at the Central California Women's Facility in Chowchilla, Calif., providing resources so these women can pursue the path to entrepreneurship. The company will separately provide general funding for the non-profit's Entrepreneurs in Training program, which makes grants available to graduates to help start and grow their own businesses. Additionally, LegalZoom will provide access to its products at no cost to help graduates of Defy's Entrepreneurship Pathway program form businesses and get access to the legal and compliance resources they need.

09:06 EDT Synopsys initiates $175M accelerated share repurchase agreement - Synopsys announced that it has entered into an accelerated share repurchase agreement with HSBC Bank USA, National Association to repurchase an aggregate of $175M of Synopsys stock. Under the terms of the ASR, Synopsys will receive an aggregate initial share delivery of approximately 431,000 shares, with the remainder, if any, to be settled on or before November 24, upon completion of the repurchases. The specific number of shares that Synopsys ultimately repurchases under the ASR will be based on the average of Synopsys' daily volume-weighted average share prices during the repurchase period, less a discount.

09:05 EDT Agenus announces results from Phase 2 study of balstilimab published - Agenus announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer reviewed journal Gynecologic Oncology. "Publication of these data marks another significant achievement toward our objective to provide effective therapeutic options to those battling cancer," said Steven O'Day, MD, Chief Medical Officer of Agenus. "These data are drawn from the largest Phase 2 study to date evaluating PD-1 inhibition in advanced cervical cancer patients who have progressed on or after first-line chemotherapy; the results indicate balstilimab's potential as an effective new therapy." In the 140 evaluable patients, the objective response rate in patients with PD-L1 positive tumors was 20.0% and included 3 patients with a complete response and 14 patients with a partial response. The median duration of response, or DoR, was not reached after a 14.6-month median follow-up. Responses were also observed in the PD-L1 negative population with an ORR of 7.9%. The confirmed ORR for both PD-L1 positive and negative tumors was 15.0% and included 5 patient with a complete response and 16 patients with a partial response. The median DoR was 15.4 months and the disease control rate was ~50%. The safety profile was manageable and consistent with that of currently approved anti-PD-1 antibodies. As discussed in the publication, these data suggest that balstilimab may be a differentiated anti-PD-1 antibody as compared to currently approved PD-1 inhibitors. In the KEYNOTE-158 trial of pembrolizumab, an anti-PD-1 antibody, in the same setting, an ORR of 14.6% was observed in the PD-L1 positive population and no responses were observed in the PD-L1 negative population. In addition, the noted 12.5% response rate of balstilimab in patients with cervical adenocarcinoma is significant as this subpopulation typically does not respond to immunotherapy and represents a growing proportion of advanced cervical cancer cases. Balstilimab thus provides the potential for therapeutic benefit to patient populations that do not typically respond to currently-available immunotherapy, both alone and in combination with other therapies, such as Agenus' anti-CTLA-4 antibodies zalifrelimab and AGEN1181.

09:04 EDT Revlon names Thomas Cho chief supply chain officer - Revlon announced the hire of Thomas Cho as chief supply chain officer. In this position, Cho will be responsible for Revlon's end to end global supply chain operations, including supply chain strategy, planning, procurement, manufacturing, engineering, distribution and logistics for the company's diverse brand portfolio across all channels and geographies. Cho officially joined Revlon on August 2 and reports to the president and CEO, Debra Perelman. Cho joins Revlon from PPI Beauty in Chicago, where he held the position of COO.

09:03 EDT ZipDoctor executes telemedicine services agreement with Texas pharmacy - American International Holdings announced its wholly-owned subsidiary, ZipDoctor, Inc., has executed a telemedicine services agreement with Murphy RX, a Texas-based specialty pharmacy that provides its customers with prescriptions, specialty compounding, vaccinations, diabetes care, medical equipment, various OTC remedies, as well as a full range of cosmetic products, vitamins and more. Under the terms of the Agreement, ZipDoctor will develop and provide Murphy with access to a centralized technology platform to collect and manage patient demographics, insurance information, and collect acute health information for the purpose of being reviewed for treatment by ZipDoctor's network of providers. Murphy will offer its customers/patients access to ZipDoctor's suite of telemedicine services currently available through its website at www.ZipDoctor.co with all telemedicine services being provided by ZipDoctor and its network of providers. Murphy will pay ZipDoctor a monthly fee on a per-patient basis for the use of the technology platform and for access to its currently available primary care telemedicine services.

09:01 EDT Montauk Renewables awarded patent for near-zero-emissions renewable energy tech - Montauk Renewables announced the Company has been awarded patent number US11,097,245, issued by the U.S. Patent & Trademark Office covering 24 unique elements of its Electric-Powered, Closed-Loop, Continuous-Feed, Endothermic Energy-Conversion Systems and Methods. The System enables near-zero-emissions conversion of agricultural waste into multiple non-fossil, renewable-fuel alternatives, is capable of producing approximately 10-units of renewable energy for each unit of conventional energy consumed and sequestering approximately 25-tons of greenhouse gas equivalent emissions for every single ton emitted. The System is driven by a continuous-feed, closed loop reactor that can scale modularly to address the environmental challenges of industrial agriculture, regardless of location or size. As previously announced, Montauk intends to initially deploy its newly patented technology through a large-scale development project in North Carolina. The now patented System has the potential to generate expansive growth opportunities through systematic nation-wide deployment and global licensing agreements.

08:40 EDT Forbes to become public through Magnum Opus Acquisition combination - Forbes and Magnum Opus Acquisition announced that they have entered into a definitive business combination agreement. The transaction is expected to close in late Q4 or early Q1 of 2022. Forbes' existing management team will continue to manage the combined company upon completion of the transaction under the leadership of CEO Mike Federle. The combined company will announce new, independent members to its board at a later date. The transaction values the combined company at an implied pro forma enterprise value of $630M, net of tax benefits. The transaction has been approved by the boards of directors of both Forbes and Magnum Opus. The transaction is expected to close in late Q4 or early Q1, subject to the satisfaction of customary closing conditions, including the approval of Magnum Opus' shareholders. The transaction is expected to raise approximately $600M of gross proceeds consisting of the contribution of approximately $200M of cash held in Magnum Opus' trust account, assuming no redemptions by the public shareholders of Magnum Opus, and $400M of additional capital through a private placement of ordinary shares of the combined companypriced at $10.00 per share from funds and accounts managed by institutional investors. Assuming no redemptions by the public shareholders of Magnum Opus, Forbes shareholders will own approximately 22% of the combined company at closing. Forbes will be capitalized with up to $145M in cash.

08:38 EDT Mullen Technologies to debut Mullen FIVE EV Crossover at LAIAS - Mullen Technologies, which previously announced a definitive agreement to merge with Net Element in a stock-for-stock reverse merger in which Mullen's stockholders will receive a majority of the outstanding stock in the post-merger company, announced the debut date of the Mullen FIVE EV Crossover. Mullen will debut to the world, for the first time, the FIVE EV Crossover on Nov. 17, 2021, at the Los Angeles International Auto Show.

08:37 EDT Primoris awarded two new solar contracts valued over $120M - Primoris announced two new solar awards with a combined value of over $120M. The contracts were secured by the company's Energy/Renewables segment. The first award is for the engineering, procurement, and construction of a utility-scale solar facility in the Southwest. The primary scope includes all civil, electrical and mechanical work. Initial construction on the project will begin in Q3 of 2021 with completion expected in Q3 of 2022. The second award is for the engineering, procurement, and construction of a utility-scale solar facility in the Midwest. The scope includes all civil, electrical and mechanical work. Initial construction on this project will begin in the third quarter of 2021 with completion expected in Q2 of 2022.

08:36 EDT CytoDyn holders file suit to get holders vote in alternative director nominees - A group of long-time stockholders of CytoDyn that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today announced that it has filed a lawsuit in the Delaware Court of Chancery seeking to force CYDY to allow stockholders to vote for the Group's nominees. CYDY has previously filed litigation seeking to block the ability of stockholders to vote for the Group's nominees as an alternative to the current CYDY Board and has issued several communications falsely stating that stockholders cannot do so. The Group stated, "The current CytoDyn Board has repeatedly failed to secure FDA approval for the Company's groundbreaking Leronlimab drug, which has the potential to improve the lives of people suffering from several conditions. Given the Board's value-destructive failures and snowballing legal and regulatory issues, we have nominated five exceptionally qualified candidates to serve on the Board and utilize their considerable expertise to achieve the Company's core objectives of obtaining FDA approval for Leronlimab and reinvigorating CYDY. We will not stand by while the incumbent Board and management team files meritless lawsuits and issues false press releases, in addition to their corrupt behaviors and efforts to entrench themselves, in order to continue collecting their outsized pay packages. The time has come for stockholders to have this choice and we will fight to protect the stockholders' fundamental right to vote on CYDY's leadership while the Company illegally and irresponsibly fights to deprive them from doing so. If the current Board and management team are confident in their performance to date, why are they afraid to let stockholders vote?"

08:34 EDT ABVC BioPharma says FDA requests additional information on Vitargus - ABVC BioPharma provided an update regarding recent developments in connection with Vitargus, a bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. Early clinical studies indicate that Vitargus has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products. These developments include: ABVC has selected the first clinical study site and principal investigator for conducting a Phase II clinical study of Vitargus in Australia. The objective of the study "A Prospective Multi-Site Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV1701 Ocular Endotamponade" is to demonstrate the safety and effectiveness of Vitargus when compared to the commonly used SF6 Gas OE. Approval of the study by the Australian Therapeutic Goods Administration is expected in Q4 of 2021 with first patient enrollments beginning during Q1 of 2022. As previously disclosed, ABVC held a meeting with the US FDA on May 20, 2021, to review FDA comments regarding the results of the Vitargus Phase I studies. The FDA requested additional data, primarily involving animal studies, which the company expects to provide early in 2022. ABVC was encouraged by the FDA discussion and strongly believes that the efficacy and safety of Vitargus will be confirmed by the requested studies. The company continues to have active discussions with several large pharmaceutical companies interested in becoming distribution and/or manufacturing partners for Vitargus.

08:32 EDT Saratoga Investment board increases quarterly dividend to 52c per share from 44c - Saratoga Investment announced that its Board of Directors has declared a quarterly dividend of 52c per share for the fiscal quarter ended August 31, 2021, payable on September 28, 2021, to all stockholders of record at the close of business on September 14, 2021. This is an increase of 8c per share from 44c per share last quarter. "We are very pleased that our strong track record and portfolio performance, healthy credit profile, robust deal pipeline, and ongoing asset growth continue to generate strong, consistent financial performance in support of a program of paying and increasing quarterly dividends," said Christian Oberbeck, Chairman and Chief Executive Officer of Saratoga Investment. "This positive performance across all metrics has allowed us to increase our dividend this quarter by 8c, or 18%, to 52c per share. In concluding on this level of increase, we also took into consideration our current and projected level of spillover and ensuring we manage that appropriately. Our dividend strategy is consistent with our overall approach to managing risk conservatively, while pursuing long-term growth and credit quality. We will continue to evaluate dividend payments on a quarterly basis taking into account portfolio and investment performance, along with the prospects for continued economic recovery and growth."

08:20 EDT Triterras announces listing extension granted by Nasdaq - Triterras announced that the company received notice from the Listing Qualifications Department of the NASDAQ Stock Market that its request for an extension to regain compliance with the Nasdaq Listing Rules has been granted. The company has until November 1, 2021 to file its Annual Report on Form 20-F for the fiscal year ended February 28, 2021 with the U.S. Securities and Exchange Commission. As previously disclosed, Triterras received a notice from the Listing Qualifications Department of Nasdaq on July 1, 2021 stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed its 2021 Annual Report with the U.S. Securities and Exchange Commission. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required public financial reports with the SEC.

08:16 EDT NV5 Global appoints Denise Dickins to board of directors - NV5 Global announced the appointment of Denise Dickins, Ph.D., CPA, CIA to the NV5 Board of Directors. Dickins is a Professor of Accounting and Auditing at East Carolina University. She has served on the board of directors for several publicly traded companies. Dickins was approved by the NV5 Board of Directors and will fill the board position previously held by Michael Renshaw who resigned from the Board of Directors in August 2021 due to perceived conflicts of interest.

08:14 EDT Heat Biologics launches Skunkworx Bio, new drug discovery subsidary - Heat Biologics announced the launch of its wholly-owned subsidiary, Skunkworx Bio, focused on the development of a drug discovery paradigm to enable rapid drug development. Jeff Wolf, Chief Executive Officer of Heat, commented, "We are extremely proud to launch Skunkworx, an innovative platform to accelerate the path from discovery to preclinical development. Skunkworx augments Heat's emerging drug development ecosystem designed to efficiently move new biologic programs from discovery into the clinic. New programs will be discovered through Skunkworx, developed at Heat and manufactured at Scorpion Biological Services, Heat's wholly owned manufacturing subsidiary. This integrated platform is focused on driving innovation by rapidly accelerating the drug development process. We look forward to working with Skunkworx to advance a wide repertoire of drugs across a wide variety of indications, including biosecurity applications, an area of growing importance."

08:10 EDT Pingtan Marine Enterprise receives additional Nasdaq noncompliance letter - Pingtan Marine Enterprise has received an additional delinquency notification letter from Nasdaq indicating that, since the company remains delinquent in filing its Annual Report on Form 10-K for FY20 and its Q1 and Q2 Quarterly Reports on Form 10-Q, the company is not in compliance with the timely filing requirement for continued listing. Pingtan submitted a plan to Nasdaq on June 14 outlining its plan to regain compliance with respect to these delinquent reports. The company continues to engage in discussions with Nasdaq regarding its plan to regain compliance. The company anticipates filing the Form 10-K, Q1 Form 10-Q and Q2 Form 10-Q on or before October 12. The company will continue to work to complete and file the delinquent reports as soon as practicable.

08:10 EDT Alignment Healthcare launches PPO Plan with Scripps Health in San Diego county - Medicare Advantage company Alignment Healthcare announced the addition of a new PPO plan option with Scripps Health to its San Diego County network starting January 1, 2022, pending regulatory approval. "This exclusive PPO product offers access to Scripps' vast network of resources including Scripps Coastal Medical Center, Scripps Clinic, Scripps HealthExpress and Scripps hospitals," said Dawn Maroney, markets president, Alignment Healthcare, and CEO, Alignment Health Plan. "As Alignment broadens its footprint throughout California, we are delighted to provide our San Diego members with greater access to top doctors and health services in 2022 and beyond."

08:08 EDT Sunworks, CBG Building to provide 752.4kW carport solar system at UC Davis - Sunworks announced that it has signed an agreement with CBG Building to provide a 752.4kW carport solar system for Orchard Park, a 1,549-bed student housing project on the University of California, Davis campus.

08:07 EDT iSun announces multiple project awards in Vermont exceeding $7M - iSun announced that it has been awarded 11 projects for Solar Engineering, Procurement and Construction, EPC, services in its home state of Vermont. iSun estimates that the portfolio will have a combined contract value exceeding $7M. "We're always excited to communicate progress towards our three-pronged strategy for growth to our investors," said Jeffrey Peck, Chairman and Chief Executive Officer of iSun. "We're particularly proud when such news happens in our own backyard. Again, since first announcing this strategy in late 2019, we've maintained that our relationships and reputation within regions where we're more established will provide springboards for continued growth opportunities. These Vermont contracts are proof of exactly that."

08:07 EDT Pardes Biosciences initiates first-in-human trial for PBI-0451 - Pardes Biosciences announced the initiation of a Phase 1 clinical trial, evaluating the company's lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. In preclinical studies, PBI-0451 has been shown to inhibit replication of a broad range of coronaviruses including SARS-CoV-2 across multiple in-vitro models, and was well tolerated in clinically enabling toxicity studies. The Phase 1 study will be a placebo-controlled, blinded, randomized, dose escalation study of PBI-0451 in healthy volunteers designed to evaluate the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses, and will also explore the drug-drug interaction potential of PBI-0451. This first-in-human study is designed to explore the potential for dosing PBI-0451 as a once or twice-a-day pill and is anticipated to enroll up to 110 healthy volunteers. The company anticipates reporting clinical data from this Phase 1 study in the fourth quarter of 2021. On June 29, 2021, Pardes entered into a definitive Agreement and Plan of Merger with FS Development Corp. II. a special purpose acquisition company.

08:06 EDT DayDayCook announces merger agreement with Ace Global Business Acquisition - DayDayCook announces that it has entered into a definitive merger agreement with Ace Global Business Acquisition providing for a business combination that will result in DayDayCook becoming a publicly listed company. Upon closing of the transactions, the parties plan to remain NASDAQ-listed under a new ticker symbol. As part of the transaction, Ace aims to complete a private investment in public equity of approximately $30-40MM, and the combined company will have a pro forma firm value of approximately $377-387MM at closing, assuming no shareholder redemption. DayDayCook will receive $46.9MM in cash from Ace's trust account. DayDayCook's current management team will continue running the combined Company after the transaction. The RTC market size is expected to grow at 20% CAGR to reach USD 150bn in 2027, driven by structural changes in consumer behavior and preferences. DDC is well positioned to capture this opportunity, leveraging its Omni-channel sales strategy to span across traditional e-commerce, social-commerce, and offline retailer networks. The company also has strategic partnerships with key manufacturers to build a strong and nimble supply chain. DayDayCook has also launched plant-based products to address the rising demand for healthier meal choices amongst consumers as well as to promote a quality lifestyle to the company's customer base. Increasing contribution from plant-based products both in terms of revenue and number of SKUs is a core strategy for DDC. This month, DayDayCook announced a strategic investment with Proterra, further strengthening the company's commitment in future plant-based business developments. Under the terms of the Merger Agreement, Ace will acquire DDC, resulting in DDC being a listed company on the Nasdaq Capital Market. At the effective time of the transaction, DDC's shareholders and management will receive 30 million shares of Ace's common stock. In addition, DDC shareholders will be entitled to receive earn-out consideration of up to an additional 3.6 million shares of Ace's common stock, subject to DDC achieving certain share price thresholds and revenue targets prior to certain future dates, as set forth in the Merger Agreement.

08:04 EDT Pfizer announces Aamir Malik has joined as Chief Business Innovation Officer - Pfizer announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer's Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla. Mr. Malik joins Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm's U.S. operations. Previously, he led the firm's Global Pharmaceuticals & Medical Products practice. Malik succeeds John Young, Executive Vice President and Chief Business Officer, who recently announced his intent to retire after a 34-year career at Pfizer. Mr. Malik begins his role on August 30, 2021 and will work with John to ensure a seamless transition. At Pfizer, Mr. Malik will oversee the company's strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payers and governments around the world. "We are delighted to welcome Aamir Malik to our executive leadership team in this important role as we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to reimagine how we do business for the benefit of patients and society," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "Aamir brings with him 25 years of experience developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs to improve patients' lives and transform performance for life science companies. He is the ideal leader to drive these efforts."

08:03 EDT Thor Industries enters two-year partnership with Girl Scouts of the USA - Thor Industries has entered a two-year partnership with Girl Scouts of the USA. The partnership underscores Thor's continued commitment to promoting inclusivity in the outdoors. As part of the commitment, Thor will be sponsoring GSUSA's largest and most popular outdoor event, Girl Scouts Love State Parks. The annual event is hosted in nearly 500 state parks across all 50 states and Puerto Rico. The 2021 event, occurring September 11 and 12, will be focused on inclusivity and park stewardship in response to COVID's impact on public lands. As part of the sponsorship, Girl Scouts is incorporating Thor's own sustainability program, Pick Up America, into its park stewardship efforts. Since the program's launch in 2019, participants have pledged to remove over 240 tons of trash from public lands. Any of the nearly 100,000 Girl Scouts and families expected to participate may pledge to remove bags of trash from public lands through a custom-designed, co-branded Pick Up America website.

08:02 EDT Orange County Supervisor of Elections Office selects BIO-key PortalGuard - BIO-key International announced that Florida's Orange County Supervisor of Elections Office has selected BIO-key's PortalGuard Identity and Access Management platform to provide secure, multi-factor authentication and access to voter data and files in Florida's fifth-largest county. The decision builds on the Office's earlier deployment of BIO-key's fingerprint biometric solutions.

08:02 EDT Quantum to acquire assets of EnCloudEn, terms not disclosed - Quantum announced a definitive agreement to acquire the assets of EnCloudEn, an early stage hyperconverged infrastructure software company. This agreement follows Quantum's recent acquisition of the surveillance business assets of Pivot3, an early pioneer of hyperconverged infrastructure for video surveillance workloads. The EnCloudEn acquisition will enable Quantum to expand the addressable market for the company's video surveillance portfolio, offering customers a solution using their server hardware of choice with a flexible subscription-based software model. EnCloudEn's approach to simplicity and automation integrates tightly with Quantum's strategy to offer customers intuitive end-to-end solutions for the video data lifecycle. The asset acquisition is expected to close later this quarter and is subject to customary closing conditions.

07:44 EDT Edesa gives update on clinical study on monoclonal antibody candidate for Covid - Edesa Biotech provided an update on a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate as a single-dose therapy for hospitalized COVID-19 patients.As of August 25, Edesa reported that more than 525 subjects have been randomized into the study to be treated with either Edesa's monoclonal antibody, designated EB05, plus standard of care treatment, or placebo plus standard of care. Approximately 35 of these patients have been assigned to an investigation sub-study evaluating EB05 as a rescue therapy for patients with critically severe COVID-19 symptoms, including patients who have been ventilated for more than five days or are receiving extracorporeal membrane oxygenation therapy. Additionally, the company reported that all patients planned for a key interim analysis have been randomized and completed the treatment protocol. Edesa expects the analysis from third-party statisticians to be completed in the coming weeks.The company said that the interim analysis will include data from approximately 316 subjects. The blinded comparative interim analysis of treatment data and events is expected to inform patient segmentation and associated endpoints for the final part of study. As a Phase 2/3 study, enrollment has continued during the analysis.

07:36 EDT Minim launches MikroTik router firmware management feature - Minim announced that its WiFi as a Service platform can directly manage MikroTik device firmware in subscriber homes. The new feature enhances subscriber network security by ensuring timely device updates and centralized device visibility for the Internet Service Provider. It also eliminates time, cost, and complexity for ISPs that manually manage these updates; individual updates can take an IT team an average of 10 to 15 minutes per router to perform.

07:35 EDT Burlington Stores reports Q2 SSS up 19% vs. 2Q19 - Gross margin rate was 42.2% vs. 41.4% for the second quarter of FY19, an increase of 80 basis points.

07:32 EDT Ecoark Holdings announces plans for spin-off of Trend Discovery subsidiary - Ecoark Holdings announced its plan to spin-off its subsidiary, Trend Discovery Holdings, and its subsidiaries into a new independent publicly traded company through a pro rata distribution of Trend's common stock to Ecoark's shareholders. Ecoark plans to distribute approximately 80% of the common stock of Trend to its shareholders as of a future record date to be determined upon completion of regulatory compliance. The Company, via its holding company model, plans to retain the remaining 20% ownership in Trend on its balance sheet. Ecoark's Board of Directors unanimously authorized management to proceed with the spin off. Brad Hoagland, CFA, Chief Financial Officer of Ecoark is expected to assume the role of Chief Investment Officer of Trend, while retaining the role of Chief Financial Officer of Ecoark until a long-term successor has been named. The transaction is expected to close in the calendar fourth quarter of 2021, subject to the satisfaction of customary conditions, and the effectiveness of a Form 10 registration statement to be filed with the Securities and Exchange Commission. The exchange listing is subject to meeting applicable listing requirements. "We are constantly exploring opportunities to generate shareholder value, and firmly believe that this transaction unlocks a greater value of the Trend asset relative to its valuation as part of Ecoark's current portfolio," stated Randy May, Chief Executive Officer of Ecoark. "We believe, Trend will be positioned to excel in the FinTech market with the platform and resources of a pure-play, stand-alone publicly traded company."

07:25 EDT Shutterstock Editorial launches Rights And Clearance service - Shutterstock is launching Rights and Clearance, a service for Shutterstock's global customer base that obtains third party permissions across the entire portfolio of assets for promotional use in advertisements, social campaigns, marketing materials and more. Shutterstock's Rights and Clearance service connects Shutterstock's customers with a team of global experts for content clearing and permissions across an array of promotional uses. Shutterstock's Rights and Clearance is an extension of Asset Assurance, a service launched in 2020 for licensing editorial images and footage for commercial and creative campaigns.

07:17 EDT BurgerFi partners with ICR for investor relations efforts - BurgerFi International announced that it has engaged ICR, a strategic communications advisory firm, to manage its investor relations program.

07:16 EDT Paramount Gold to acquire 100% interest in Bald Peak Project from Nevada Select - Paramount Gold Nevada Corp. (PZG) announced today that it has entered into an agreement with Nevada Select Royalty to purchase a 100% interest in the Bald Peak Project located in Mineral County, Nevada. Nevada Select is a wholly owned subsidiary of Ely Gold Royalties Inc., which was recently acquired by Gold Royalty Corp. (GROY). Bald Peak is a large gold and silver epithermal system with several miles of prospective ground in the prolific, Bodie-Aurora-Borealis district which has produced over 3 million ounces of gold from open pit mines. Gold and silver mineralization is associated with strongly silicified rock in a well-defined 4-mile-long structural system. Surface outcropping has returned rock samples grading over 8 g/T gold. The gold-bearing silicified material exhibits a strong, easy-to-follow resistivity signature. During due diligence, the Paramount technical team identified an alteration system stretching beyond the Bald Peak property and has staked additional claims extending towards Hecla Mining's Aurora Mine. Paramount's plan is to initiate surface sampling, geological reconnaissance, and a subsequent geophysical survey to map silicification at depth to identify drill targets. Paramount has the right to acquire a 100% interest in the Bald Peak Project for total consideration of $300,000 payable to Nevada Select as follows: $20,000 on closing of the transaction; $30,000 upon the receipt of a drilling permit; $50,000 one year following the Permit Date; $50,000 due on each of the second and third years following the Permit Date; and A final payment of $100,000 four years following the Permit Date. Nevada Select, upon option exercise, will retain a 3% Net Smelter Royalty, on the Nevada Select Claims Paramount has the right to reduce the NSR to 2% for a payment of $1 million.

07:15 EDT IceCure Medical to begin trading on Nasdaq Capital Market - IceCure Medical announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market. The company's shares will begin trading on Nasdaq on August 26 at market open under the ticker symbol "ICCM." The company will maintain the listing of its ordinary shares on the Tel Aviv Stock Exchange under the symbol "ICCM."

07:12 EDT Noble Corp. divesting four jackups in Saudi Arabia - Noble Corporation subsidiaries have reached a definitive agreement to sell four jackups to ADES International Holding through its subsidiary for $292M. The company expects to generate approximately $285M in cash from the transaction net of fees, expenses, and the settlement of working capital. The Noble Roger Lewis, Noble Scott Marks, Noble Joe Knight, and Noble Johnny Whitstine will be sold and the current drilling contracts novated to ADES. Closing is expected before the end of October and is subject to the satisfaction of closing conditions. The company updated 2021 guidance, and preliminary 2022 guidance, pro forma for the divestiture,

07:12 EDT BioCryst appoints Steven Galson to board of directors - BioCryst Pharmaceuticals (BCRX) announced that the company has appointed former director of the U.S. Food and Drug Administration Center for Drug Evaluation and Research, and former acting surgeon general, Steven Galson, M.D., MPH to its board of directors. Most recently, Dr. Galson served as the senior vice president, research and development at Amgen (AMGN).

07:10 EDT Kaixin Auto signs binding term sheet to acquire EV manufacturer - Kaixin Auto announced that the company has reached a binding term sheet to acquire 100% equity of Henan Yujie Times Automobile through new share issuance. The contemplated deal would be the first major M&A transaction following the establishment of Kaixin's New Energy Vehicle Unit. It marks Kaixin's official entry into China's small size EV market. "The signing of term sheet represents a major breakthrough for Kaixin to enter the EV field, and constitutes a step toward the vision of establishing its own EV eco-system and becoming a leading Chinese EV manufacturer. The Company will negotiate further details of an acquisition agreement with Yujie consistent with the term sheet, and make timely disclosure of progress," the company said.

07:09 EDT Enthusiast Gaming reports high of Unique Visitor traffic in the U.S. in July - Enthusiast Gaming Holdings is pleased to announce that Unique Visitor traffic in the U.S. to its digital media property has reached a 2021 high in July, based on recent data from Comscore, a leading third party media measurement and analytics company. Enthusiast Gaming's Unique Visitors in the U.S. grew to 45.3 million in July, an increase of 9% over June. That made July the highest month for U.S. Unique Visitor traffic thus far in 2021. The metric does not include additional under 18 mobile video traffic to the Company's property, or viewership in the Company's esports and entertainment division, including viewership of Luminosity Gaming.

07:08 EDT Cigna expands, enhances ACA marketplace plans - Cigna is expanding its offerings to customers who access health coverage through the Affordable Care Act marketplace. During the upcoming Open Enrollment Period, Cigna plans will be available to Marketplace customers in three new states - Georgia, Mississippi and Pennsylvania - as well as in additional counties in Arizona, Florida and Virginia. With this expansion, pending final regulatory approvals, Cigna will offer individual and family plans on the individual exchanges in 313 counties spanning 13 states including Arizona, Colorado, Florida, Georgia, Illinois, Kansas, Mississippi, Missouri, North Carolina, Pennsylvania, Tennessee, Utah and Virginia. These new markets have the potential to reach approximately 1.5M additional customers.

07:07 EDT BeyondSpring enters commercialization agreement with Hengrui for plinabulin - BeyondSpring and Jiangsu Hengrui Pharmaceuticals announced an exclusive commercialization and co-development agreement in Greater China for BeyondSpring's investigational drug candidate plinabulin, a first-in-class, selective immunomodulating microtubule-binding agent. Plinabulin in combination with G-CSF is currently under NDA Priority Review by the U.S. Food and Drug Administration and the China National Medical Products Administration for the prevention of chemotherapy-induced neutropenia. BeyondSpring recently announced positive topline Phase 3 results from its DUBLIN-3 study of plinabulin in combination with docetaxel for the treatment of 2nd and 3rd line, EGFR wild-type non-small cell lung cancer. BeyondSpring will still retain 100% of the global plinabulin rights outside of Greater China. Under the terms of the agreement, Wanchunbulin will grant Hengrui exclusive rights to commercialize and co-develop plinabulin in the Greater China markets, including mainland China, Hong Kong, Macau and Taiwan. Wanchunbulin will retain the manufacturing rights of plinabulin in the Territory and will book all plinabulin revenue in the Territory. Hengrui will receive a pre-determined percentage of the net sales in each quarter. Wanchunbulin will receive the equivalent of up to 1.3B RMB, including an upfront payment of 200M RMB and regulatory and sales milestones of up to 1.1 B RMB. Hengrui will be responsible for all costs associated with commercialization of plinabulin in the Territory. Pursuant to the terms, Wanchunbulin will be responsible for 100% of the clinical and regulatory costs for the first two indications for plinabulin: prevention of CIN and 2nd/3rd line treatment of NSCLC. Hengrui will fund 50% of the clinical development costs for additional indications for plinabulin in the Territory, with a Joint Steering Committee overseeing the clinical strategy and priorities. With deep understanding of plinabulin and its potential, Wanchunbulin will lead the protocol design and development for additional indications. In connection with the signing of the collaboration, Hengrui will make an equity investment at 100M RMB into the Wanchunbulin subsidiary at a pre-money valuation of 3.6B RMB.

07:06 EDT Skylight Health appoints Mohammad Bataineh as President - Skylight Health Group announced the appointment of Mohammad Bataineh as the company's new President. Bataineh will be responsible for management and execution of all internal functions including coordination with clinical, financial, and technology teams. Co-Founder Kash Qureshi will shift focus to Corporate Affairs, including Corporate Development, and will retain executive leadership while overseeing the Technology and Data Analytics teams. Qureshi remains an Executive Member of the Board of Directors. The company has also removed the Chief Operations Role and will see Paul Kulas depart as part of this change. Operations, along with support functions, will now report directly into the President, and will work in close collaboration with Clinical, Finance and Technology teams.

07:05 EDT Renalytix AI announces publication of results from budget impact analysis - Renalytix announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion for a population of 100,000 patients with type 2 diabetes and chronic kidney disease tested with the Renalytix KidneyIntelX testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure.The detailed clinical and cost analysis concluded that health systems and insurance plans would realize these significant cost savings based on slowed disease progression, delayed, or prevented dialysis and transplants, and reduced dialysis crashes. Given the costs associated with current standard of care, the addition of an actionable bioprognostic approach to predict kidney function decline in T2DKD patients, stages 1-3b resulted in a projected 5-year savings of $1.1 billion associated with KidneyIntelX. Budget impact analysis is a key element in securing payer coverage in the U.S. market. BIA is an economic assessment that estimates the financial consequences of adopting a new, high value intervention like KidneyIntelX. The analysis takes a payer's perspective to evaluate whether a new intervention is affordable. It uses a short-term time horizon, up to 5 years. The model analyzes the direct costs of specific resources needed to implement KidneyIntelX informed care in the PCP office with savings associated with changes in care delivery. That result is multiplied by the number of people affected by the intervention. The results of the analysis provide an understanding of the total budget required to provide the intervention. The size of the population is explicitly considered for this analysis. The focus of a BIA is the direct costs of specific resources needed to put the intervention into effect, such as testing, pharmacy management, and specialist care. Consistent with best practices, sensitivity analyses were conducted to evaluate the impact of core assumptions related to physician compliance and disease progression. Renalytix will further expand its health economic and utility evidence through separate cost-effectiveness analyses evaluating whether intervention with KidneyIntelX testing provides value, defined as cost relative to health outcome, relative to current standard of care. These analyses will be completed in conjunction with three large real-world evidence studies with Mount Sinai Health System, Wake Forest/Atrium Health and University of Utah Health. The budget impact model was developed in collaboration with Boston Healthcare Associates, an external firm, in accordance with the International Society for Pharmacoeconomics and Outcomes Research good practices. BHA researchers evaluated the budget impact of management using KidneyIntelX as compared with standard of care over a 5-year horizon in patients with diabetic kidney disease. Results are detailed in, "Payer Budget Impact of an Artificial Intelligence In Vitro Diagnostic to Modify Diabetic Kidney Disease Progression," published in the Journal of Medical Economics.

07:03 EDT Lordstown Motors appoints Daniel Ninivaggi as Chief Executive Officer - Lordstown Motors (RIDE) announced that its board of directors has appointed Daniel Ninivaggi as CEO and as a member of the Board, effective immediately. Ninivaggi is the former CEO of Icahn Enterprises (IEP).

06:53 EDT NRx Pharmaceuticals signs agreement with Cardinal Health on Zyesami distribution - NRx Pharmaceuticals (NRXP) announced it has signed an agreement with Cardinal Health (CAH) to provide third party logistics and distribution of Zyesami upon the potential Emergency Use Authorization, or EUA, approval by the FDA. In May, NRx submitted an application for EUA to the FDA for Zyesami for patients suffering from Critical COVID-19 with respiratory failure. Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for Zyesami, providing broad access to hospitals for this needed medicine upon FDA authorization. With one of the largest healthcare supply chains, Cardinal Health services more than 90% of hospitals in the U.S., and has more than 20 years of experience supporting rapid delivery of lifesaving medicines. Additionally, Cardinal Health's Third-Party Logistics Services will support the warehousing and distribution, full order to cash, and necessary title model services.

06:49 EDT Merck's KEYTRUDA receives two new approvals in Japan - Merck announced that KEYTRUDA, Merck's anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency. KEYTRUDA is approved for the treatment of patients with PD-L1-positive, hormone receptor-negative and human epidermal growth factor receptor 2-negative, inoperable or recurrent breast cancer, based on the results of the Phase 3 KEYNOTE-355 trial. Additionally, KEYTRUDA as a monotherapy is approved for the treatment of patients with unresectable, advanced or recurrent high microsatellite instability colorectal cancer, based on results of the Phase 3 KEYNOTE-177 trial. With these approvals, KEYTRUDA has 15 authorized uses in Japan, including indications in nine tumor types as well as MSI-H tumors.

06:48 EDT Pfizer, BioNTech partner with Eurofarma to manufacture COVID-19 vaccine doses - Pfizer (PFE) and BioNTech SE (BNTX) announced the signing of a letter of intent with Eurofarma Laboratorios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY for distribution within Latin America. Eurofarma will perform manufacturing activities within Pfizer's and BioNTech's global COVID-19 vaccine supply chain and manufacturing network, which will now span four continents and include more than 20 manufacturing facilities. To facilitate Eurofarma's involvement in the process, technical transfer, on-site development, and equipment installation activities will begin immediately. Per the agreement, Eurofarma will obtain drug product from facilities in the U.S., and manufacturing of finished doses will commence in 2022. At full operational capacity, the annual production is expected to exceed 100 million finished doses annually. All doses will exclusively be distributed within Latin America.

06:40 EDT Lululemon to raise minimum base pay for majority of store, CEC workers - lululemon athletica announced a comprehensive overview of the company's approach to pay and benefits. Effective September 27, lululemon will raise the minimum base pay for the majority of its store and Guest Education Centre employees in North America. As part of the additional investments, people who are currently employed, and individuals who are hired from this point forward, will receive a new minimum of $15 or $17 per hour depending on their role and the market. In addition, employees continue to be eligible for lululemon's team-based bonus program, with the possibility to earn up to an additional $3 an hour on average, and up to $6 an hour, for store-based goals and results achieved. As lululemon continues to grow and prepares for the holiday season, the Company will be hiring more than 8,000 team members in North America across its stores and GEC. These roles will include full and part-time Educator and Key Leader positions.

06:39 EDT Lululemon to raise minimum base pay for majority of store, CEC workers - lululemon athletica announced a comprehensive overview of the company's approach to pay and benefits. Effective September 27, lululemon will raise the minimum base pay for the majority of its store and Guest Education Centre employees in North America. As part of the additional investments, people who are currently employed, and individuals who are hired from this point forward, will receive a new minimum of $15 or $17 per hour depending on their role and the market. In addition, employees continue to be eligible for lululemon's team-based bonus program, with the possibility to earn up to an additional $3 an hour on average, and up to $6 an hour, for store-based goals and results achieved. As lululemon continues to grow and prepares for the holiday season, the Company will be hiring more than 8,000 team members in North America across its stores and GEC. These roles will include full and part-time Educator and Key Leader positions.

06:38 EDT Coty confirms pursuit of partial IPO of Brazil business - In order to support the growth of the Brazil business and Coty's personal care brands, Coty confirms that it is pursuing a partial IPO of its Brazil business. Earlier today, Coty completed its first filing at CVM - the Securities Commission which regulates capital markets - in Brazil to commence this partial IPO process. If the offering is successful, this will also help advance Coty's deleveraging agenda. Coty intends to remain a controlling shareholder of the Brazil affiliate. Due to local Brazilian regulations, following its first filing Coty cannot offer further details at this time but will provide updates in due course.

06:33 EDT Hoegh LNG Partners reports Q2 EPS (4c), two estimates 38c - Reports Q2 revenue $34.7M, two estimates $35.23M. Sveinung Stohle, CEO stated: "Hoegh LNG Partners' fleet of modern, full-size FSRUs once again achieved 100% operational availability during the second quarter of 2021, generating a stable operating income in spite of the continuing challenges related to the COVID-19 pandemic. While maintaining this level of operational excellence across our fleet, we are highly focused on our pending arbitration and securing a near-term solution for the refinancing of the PGN FSRU Lampung. As always, the Partnership is truly grateful for the extraordinary effort and professionalism displayed by its seafarers during these challenging times."

06:15 EDT Greenbrier announces orders totaling 5,500 units worth $530M - Greenbrier announced new orders totaling 5,500 units valued at more than $530M received thus far during its fourth fiscal quarter that began on June 1. This increases Greenbrier's backlog and provides further visibility entering fiscal 2022. Orders announced are from a mix of customers and comprise a broad range of railcar types, including intermodal, boxcars, tanks, covered hoppers and gondolas.

06:09 EDT Bioventus invests in Trice Medical - Trice Medical announced that it received a strategic investment from Bioventus. Bioventus will receive exclusive sales and distribution rights to Trice's products outside of the U.S. Bioventus and Trice have also agreed to enter into a co-development arrangement to explore the integration of Trice technologies with certain Bioventus offerings in order to accelerate adoption of both companies' products.

06:07 EDT Decarbonization Plus Acquisition Corp. II partner Tritium adds EV supplier - Tritium, a global developer and manufacturer of direct current fast chargers for electric vehicles, announced a strategic partnership with Solcon Industries, a power electronics company developing and manufacturing industrial electronic systems. With the partnership, Solcon Industries becomes an official channel partner and service provider of Tritium's range of charging technology for EV charging infrastructure in Israel and Palestine. The partnership comes on the heels of a July 24 Israeli Ministry of Foreign Affairs announcement of the country's plans to reach zero carbon emissions by 2050, calling for a 96% reduction in greenhouse gas emissions in transportation and an 85% reduction in the electricity sector. Tritium designs its products in Australia. Tritium has previously entered into a definitive agreement for a business combination with Decarbonization Plus Acquisition Corporation II that would result in Tritium becoming a publicly listed company. Completion of the proposed transaction is subject to customary closing conditions and is expected to occur in Q4.

06:01 EDT Intel names Bruce Andrews as Chief Government Affairs Officer - Intel (INTC) announced the appointment of Bruce Andrews as corporate vice president and chief government affairs officer, effective September 7. Andrews will lead Intel's global government affairs group and oversee the company's government affairs and public policy functions and strategies. He will report to Steven Rodgers, Intel's executive vice president and general counsel. Andrews joins Intel from SoftBank Group (SFTBY), where he was senior vice president and managing partner, co-leading global government affairs.

05:51 EDT Microsoft to spend $20B over five years to advance security solutions, CEO says - Microsoft CEO Satya Nadella said via Twitter: "Thank you @POTUS for convening a critical conversation on cybersecurity. Microsoft will invest $20 billion to advance our security solutions over the next 5 years, $150 million to help US government agencies upgrade protections, and expand our cybersecurity training partnerships." Reference Link

05:09 EDT Cnooc commences Bozhong 26-3 oilfield expansion project - Cnooc announced that Bozhong 26-3 oilfield expansion project has commenced production. Bozhong 26-3 oilfield expansion project is located in the south of Bohai Sea, with average water depth of about 21 meters. In addition to fully utilizing the existing processing facilities, the project has built a new unmanned wellhead platform and a power platform. A total of eight development wells are planned, including five production wells, two water injection wells and one development and appraisal well. The project is expected to reach its peak production of approximately 2,670 barrels of crude oil per day in 2021. Cnooc Limited holds 100% interest in Bozhong 26-3 oilfield expansion project and acts as the operator.